US009636342B2

(12) **United States Patent**
Chen et al.

(10) **Patent No.: US 9,636,342 B2**
(45) **Date of Patent: May 2, 2017**

(54) **METHOD FOR TREATING PROSTATE CANCER**

(71) Applicant: **UNIVERSITY OF SOUTH CAROLINA**, Columbia, SC (US)

(72) Inventors: **Mengqian Chen**, Columbia, SC (US); **Igor Roninson**, Lexington, SC (US)

(73) Assignee: **University of South Carolina**, Columbia, SC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/439,127**

(22) PCT Filed: **Nov. 1, 2013**

(86) PCT No.: **PCT/US2013/067990**
§ 371 (c)(1),
(2) Date: **Apr. 28, 2015**

(87) PCT Pub. No.: **WO2014/071143**
PCT Pub. Date: **May 8, 2014**

(65) **Prior Publication Data**

US 2015/0272953 A1 Oct. 1, 2015

Related U.S. Application Data

(60) Provisional application No. 61/721,134, filed on Nov. 1, 2012.

(51) **Int. Cl.**
A61K 31/517 (2006.01)
A61K 31/5377 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/517*** (2013.01); ***A61K 31/5377*** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2006/0235034 A1* 10/2006 Neamati C07C 243/32 514/267

OTHER PUBLICATIONS

Haas, Michel J. CDK8 inhibitor: Senex's best thing. SciBX: Science-Business eXchange. 5(33), Aug. 23, 2012, p. 1-3.*
Schmidt, Lucy J. Gene Expression in Prostate Cancer Cells Treated With the Dual 5-Alpha-Reductase Inhibitor Dutasteride. Journal of Andrology. 25(6), (2004), 944-953.*

* cited by examiner

Primary Examiner — Samantha Shterengarts
(74) *Attorney, Agent, or Firm* — Wayne A. Keown; Verrill Dana LLP

(57) **ABSTRACT**

The invention provides a method for treating prostate cancer in a subject comprising administering to the subject an effective amount of a selective inhibitor of one or more of CDK8 and CDK19. In some embodiments the inhibitor inhibits CDK19. In some embodiments, the inhibitor inhibits CDK8 at a Kd of lower than 200 nM and/or inhibits CDK19 at a Kd of lower than 100 nM. In some embodiments, the prostate cancer is androgen independent. In some embodiments, the prostate cancer is androgen independent due to one or more of androgen receptor gene amplification, androgen receptor gene mutation, ligand-independent transactivation of androgen receptor and activation of intracellular androgen synthesis. In some embodiments, the inhibitor inhibits increased activity of NF-κB. In some embodiments, the inhibitor does not inhibit increased basal levels of NF-κB. In some embodiments, inhibition of one or more genes by AR is not inhibited.

6 Claims, 16 Drawing Sheets